Treatment

Placebo tablets for GBT021601 25 mg clinical trials

1 indexed studies · 0 currently recruiting

Authorised (with conditions)Phase II and Phase III (Integrated)
C5351004 - A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
This study is testing a new oral medicine, osivelotor, for adults with sickle cell disease. It aims to see how well it works to increase healthy blood cells and reduce pain crises, and how safe it is compared to a dummy pill.
For: Sickle Cell Disease
Germany · France